Health Care Weekly: No Surprises Act Arbiters Dropped for Poor Performance; Hims to Sell Unapproved Wellness Peptides; Telehealth Firm’s GLP-1 Ads Misleading, FDA Says; Novartis Gene Therapies Face Probe over Tumors; Quest Diagnostics Settles Kickback Claims Involving New York Giants NFL Tickets

The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. In this edition

Published on Nov 11, 2026

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2026 The Capitol Forum. All Rights Reserved.